Cargando…

A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression

BACKGROUND: Fluoxetine, bupropion, cognitive behavioral therapy (CBT), and physical therapies (modified electroconvulsive treatment or repetitive transcranial magnetic stimulation) can be used to manage melancholic depression. OBJECTIVE: To compare the efficacy and safety of various treatments in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yun, Liu, Xiaohua, Peng, Daihui, Wu, Yan, Su, Yun’ai, Xu, Jia, Ma, Xiancang, Li, Yi, Shi, Jianfei, Cheng, Xiaojing, Rong, Han, Fang, Yiru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315770/
https://www.ncbi.nlm.nih.gov/pubmed/34326642
http://dx.doi.org/10.2147/NDT.S303938
_version_ 1783729769096937472
author Wang, Yun
Liu, Xiaohua
Peng, Daihui
Wu, Yan
Su, Yun’ai
Xu, Jia
Ma, Xiancang
Li, Yi
Shi, Jianfei
Cheng, Xiaojing
Rong, Han
Fang, Yiru
author_facet Wang, Yun
Liu, Xiaohua
Peng, Daihui
Wu, Yan
Su, Yun’ai
Xu, Jia
Ma, Xiancang
Li, Yi
Shi, Jianfei
Cheng, Xiaojing
Rong, Han
Fang, Yiru
author_sort Wang, Yun
collection PubMed
description BACKGROUND: Fluoxetine, bupropion, cognitive behavioral therapy (CBT), and physical therapies (modified electroconvulsive treatment or repetitive transcranial magnetic stimulation) can be used to manage melancholic depression. OBJECTIVE: To compare the efficacy and safety of various treatments in patients with melancholic depression. METHODS: This was a preliminary multicenter randomized controlled trial that included patients with depression in their first or recurrent acute episode between September 2016 and June 2019, and randomized to fluoxetine, fluoxetine+CBT, fluoxetine+bupropion, and fluoxetine+bupropion+brain stimulation. The primary endpoint was the decrease in the 17-item Hamilton Depression Rating Scale (17-HDRS). The secondary endpoint included the scores from the Quick Inventory of Depressive Symptomatology (QIDS-SR), QOL-6, and safety. Adverse events (AEs) were monitored. The follow-ups were performed at the end of the 0th, 2nd, 4th, 6th, 8th, and 12th weeks of treatment. RESULTS: Finally, 113 patients were included in the analyses: fluoxetine (n=37), fluoxetine+CBT (n=27), fluoxetine+bupropion (n=34), and fluoxetine+bupropion+brain stimulation (n=15). The 17-HDRS and QIDS-SR scores decreased in all four groups (all P<0.05). There were no differences in the 17-HDRS scores among the four groups at the end of treatment (P=0.779), except for fluoxetine alone showing a better response regarding self-consciousness than fluoxetine+bupropion. The QOL-6 scores increased in all four groups. The occurrence of AEs among the four groups showed no significant difference (P=0.053). CONCLUSION: This preliminary trial suggests that all four interventions (fluoxetine, fluoxetine+CBT, fluoxetine+bupropion, and fluoxetine+bupropion+brain stimulation) achieved similar response and remission rates in patients with melancholic depression, but that fluoxetine had a better effect on self-consciousness than fluoxetine+bupropion. The safety profile was manageable.
format Online
Article
Text
id pubmed-8315770
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-83157702021-07-28 A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression Wang, Yun Liu, Xiaohua Peng, Daihui Wu, Yan Su, Yun’ai Xu, Jia Ma, Xiancang Li, Yi Shi, Jianfei Cheng, Xiaojing Rong, Han Fang, Yiru Neuropsychiatr Dis Treat Original Research BACKGROUND: Fluoxetine, bupropion, cognitive behavioral therapy (CBT), and physical therapies (modified electroconvulsive treatment or repetitive transcranial magnetic stimulation) can be used to manage melancholic depression. OBJECTIVE: To compare the efficacy and safety of various treatments in patients with melancholic depression. METHODS: This was a preliminary multicenter randomized controlled trial that included patients with depression in their first or recurrent acute episode between September 2016 and June 2019, and randomized to fluoxetine, fluoxetine+CBT, fluoxetine+bupropion, and fluoxetine+bupropion+brain stimulation. The primary endpoint was the decrease in the 17-item Hamilton Depression Rating Scale (17-HDRS). The secondary endpoint included the scores from the Quick Inventory of Depressive Symptomatology (QIDS-SR), QOL-6, and safety. Adverse events (AEs) were monitored. The follow-ups were performed at the end of the 0th, 2nd, 4th, 6th, 8th, and 12th weeks of treatment. RESULTS: Finally, 113 patients were included in the analyses: fluoxetine (n=37), fluoxetine+CBT (n=27), fluoxetine+bupropion (n=34), and fluoxetine+bupropion+brain stimulation (n=15). The 17-HDRS and QIDS-SR scores decreased in all four groups (all P<0.05). There were no differences in the 17-HDRS scores among the four groups at the end of treatment (P=0.779), except for fluoxetine alone showing a better response regarding self-consciousness than fluoxetine+bupropion. The QOL-6 scores increased in all four groups. The occurrence of AEs among the four groups showed no significant difference (P=0.053). CONCLUSION: This preliminary trial suggests that all four interventions (fluoxetine, fluoxetine+CBT, fluoxetine+bupropion, and fluoxetine+bupropion+brain stimulation) achieved similar response and remission rates in patients with melancholic depression, but that fluoxetine had a better effect on self-consciousness than fluoxetine+bupropion. The safety profile was manageable. Dove 2021-07-23 /pmc/articles/PMC8315770/ /pubmed/34326642 http://dx.doi.org/10.2147/NDT.S303938 Text en © 2021 Wang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Wang, Yun
Liu, Xiaohua
Peng, Daihui
Wu, Yan
Su, Yun’ai
Xu, Jia
Ma, Xiancang
Li, Yi
Shi, Jianfei
Cheng, Xiaojing
Rong, Han
Fang, Yiru
A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression
title A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression
title_full A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression
title_fullStr A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression
title_full_unstemmed A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression
title_short A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression
title_sort preliminary randomized controlled trial of different treatment regimens for melancholic depression
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315770/
https://www.ncbi.nlm.nih.gov/pubmed/34326642
http://dx.doi.org/10.2147/NDT.S303938
work_keys_str_mv AT wangyun apreliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression
AT liuxiaohua apreliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression
AT pengdaihui apreliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression
AT wuyan apreliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression
AT suyunai apreliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression
AT xujia apreliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression
AT maxiancang apreliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression
AT liyi apreliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression
AT shijianfei apreliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression
AT chengxiaojing apreliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression
AT ronghan apreliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression
AT fangyiru apreliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression
AT wangyun preliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression
AT liuxiaohua preliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression
AT pengdaihui preliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression
AT wuyan preliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression
AT suyunai preliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression
AT xujia preliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression
AT maxiancang preliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression
AT liyi preliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression
AT shijianfei preliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression
AT chengxiaojing preliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression
AT ronghan preliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression
AT fangyiru preliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression